188 related articles for article (PubMed ID: 21132646)
1. [Application of guidelines in clinical practice: a multicenter analysis of the treatment of membranous glomerulonephritis in Piedmont, Italy].
Rollino C; Coppo R; Giacchino F; Savoldi S; Manganaro M; Amore A; Colla L; Ferro M; Demicheli G; Berutti S; Burdese M; Paternoster G; Cravero R; Benozzi L; Vagelli G; Messuerotti A; Licata C; Bainotti S; Patti RR; Quaglia M; Costantini L; Stratta P; Segoloni G;
G Ital Nefrol; 2010; 27(6):639-48. PubMed ID: 21132646
[TBL] [Abstract][Full Text] [Related]
2. [Focal and segmental glomerulosclerosis in Piedmont and the Aosta Valley in Italy: case study and treatment].
Rollino C; Giacchino F; Savoldi S; Manganaro M; Besso L; Amore A; Ferro M; Quaglia M
G Ital Nefrol; 2013; 30(3):. PubMed ID: 23832471
[TBL] [Abstract][Full Text] [Related]
3. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
Dumoulin A; Hill GS; Montseny JJ; Meyrier A
Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of idiopathic membranous nephropathy].
Passerini P
G Ital Nefrol; 2004; 21(6):531-9. PubMed ID: 15593020
[TBL] [Abstract][Full Text] [Related]
5. [Membranous kidney diseases in adults].
Sobarzo Toro M; Vilches A
Medicina (B Aires); 2004; 64(1):59-65. PubMed ID: 15034960
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
7. An overview of immunosuppressive therapy in idiopathic membranous nephropathy.
Maas R; Hofstra JM; Wetzels JF
Minerva Med; 2012 Aug; 103(4):253-66. PubMed ID: 22805618
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
[TBL] [Abstract][Full Text] [Related]
9. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.
Alexopoulos E; Papagianni A; Tsamelashvili M; Leontsini M; Memmos D
Nephrol Dial Transplant; 2006 Nov; 21(11):3127-32. PubMed ID: 16968719
[TBL] [Abstract][Full Text] [Related]
10. ACTH and azathioprine: antiproteinuric and lipid-lowering effect in the course of idiopathic membranous glomerulonephritis.
Gigante A; Rosato E; Liberatori M; Gasperini ML; Giannakakis K; Barbano B; Cianci R; Salsano F; Amoroso A
J Biol Regul Homeost Agents; 2012; 26(1):135-8. PubMed ID: 22475105
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
12. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
13. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy.
Ponticelli C; Passerini P; Salvadori M; Manno C; Viola BF; Pasquali S; Mandolfo S; Messa P
Am J Kidney Dis; 2006 Feb; 47(2):233-40. PubMed ID: 16431252
[TBL] [Abstract][Full Text] [Related]
14. Effect of cyclosporine therapy with low doses of corticosteroids on idiopathic nephrotic syndrome.
Griveas I; Visvardis G; Papadopoulou D; Nakopolou L; Karanikas E; Gogos K; Stavianoudakis G
Artif Organs; 2010 Mar; 34(3):234-7. PubMed ID: 20447050
[TBL] [Abstract][Full Text] [Related]
15. [Immunosuppressive therapy of glomerulonephritis--controlled studies].
Ferrari P; Frey FJ
Ther Umsch; 1993 Feb; 50(2):119-29. PubMed ID: 8456416
[TBL] [Abstract][Full Text] [Related]
16. Application of artificial neural networks in estimating predictive factors and therapeutic efficacy in idiopathic membranous nephropathy.
Naumovic R; Furuncic D; Jovanovic D; Stosovic M; Basta-Jovanovic G; Lezaic V
Biomed Pharmacother; 2010 Nov; 64(9):633-8. PubMed ID: 20888177
[TBL] [Abstract][Full Text] [Related]
17. [The late results of treating membranous glomerulonephritis].
Belovezhdov N; Robeva R; Dimitrova V
Vutr Boles; 1990; 29(3):53-60. PubMed ID: 2284800
[TBL] [Abstract][Full Text] [Related]
18. [Problems with immunosuppressive agents in nephropathies with chronic renal failure].
Savoldi S; Mesiano P; Rocchietti M
G Ital Nefrol; 2008; 25 Suppl 44():S38-S47. PubMed ID: 19048585
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of membranous nephropathy with chronic renal insufficiency].
Passerini P; Leoni A
G Ital Nefrol; 2008; 25 Suppl 44():76-82. PubMed ID: 19048590
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.
Cravedi P; Sghirlanzoni MC; Marasà M; Salerno A; Remuzzi G; Ruggenenti P
Am J Nephrol; 2011; 33(5):461-8. PubMed ID: 21508634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
